The Thrive Journal · Advanced care
What “treatment-resistant depression” actually means — and what comes next
By Jay Borrego, DNP, PMHNP-BC, CRNA · Written and clinically reviewed by the author · Published September 2026 · Last clinical review: September 3, 2026 · Coral Gables, FL
“Treatment-resistant” is one of the most discouraging phrases in psychiatry — and one of the most misunderstood. Clinically, it usually means depression that hasn't responded adequately to two or more antidepressants, taken at a real dose for a real duration. It does not mean untreatable. It means the standard first steps weren't your steps.
First: was it really a fair trial?
A surprising number of “failed” medications were never truly tried — dose too low, duration too short, side effects unmanaged, or the wrong diagnosis underneath (thyroid disease, sleep apnea, ADHD, perimenopause, and bipolar-spectrum conditions all masquerade as resistant depression). A careful re-evaluation, sometimes with lab work and pharmacogenomic context, is step one — not another random medication.
Then: the escalation ladder
When depression is genuinely treatment-resistant, there is a real ladder with evidence at each rung: optimizing or augmenting medication; structured therapy; Spravato® (esketamine), FDA-approved for exactly this situation and often insurance-covered; IV ketamine, studied head-to-head against ECT in the ELEKT-D trial with a 55.4% response rate over three weeks; and TMS. The point isn't any single treatment — it's that a plan exists past the point where most care stops.
What to ask any clinic (including ours)
How will you measure whether I'm improving? What happens if this doesn't work — what's the next rung? Who monitors me during advanced treatments, and what's their training? If a practice can't answer those three plainly, keep looking. Depression that resists treatment deserves a team that doesn't shrug — it escalates, measures, and tells you the truth at every step.
See how we structure this on the psychiatry page and the advanced pathways page.
This article is educational and not a substitute for an evaluation. Individual results vary.
References
-
Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
-
Gaynes BN, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134-145.
-
Anand A, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (ELEKT-D). N Engl J Med. 2023;388(25):2315-2325.
-
Spravato® (esketamine) Prescribing Information. Janssen Pharmaceuticals. Current label.